Evolent Health (EVH) William Blair 44th Annual Growth Stock Conference summary

Key business highlights

• Focuses on value-based specialty care for oncology, cardiology, and musculoskeletal conditions, aiming to improve quality and reduce costs by 20% over time.

• Serves major U.S. health plans, with less than 5% market penetration in a $150 billion addressable market and $50 billion cross-sell opportunity within existing clients.

• Demonstrates strong organic growth, high EBITDA and cash flow, and a history of divesting non-core assets to sharpen focus.

• Maintains high customer satisfaction and retention, with significant runway for deeper penetration among top clients.

• Growth levers include adding new partners, expanding member coverage, cross-selling products, and converting clients to higher-margin risk-based offerings.

Financial performance and guidance

• Achieved over 40% growth (excluding divestitures) and targets a $300 million EBITDA run rate by year-end, with a $75 million quarterly run rate.

• 70% of EBITDA comes from high-margin Tech & Services, while 30% is from risk-based products, with proven margin maturation over time.

• Confident in meeting full-year guidance and long-term growth and margin targets, supported by positive recent client conversations.

Strategic initiatives and capital allocation

• Prioritizes organic R&D, disciplined M&A, and maintaining reasonable leverage.

• Recent M&A includes the acquisition of NIA, which added 1,000+ staff and reduced the effective purchase multiple by 45% through synergies.

• Acquired AI assets from Machinify for $25 million, gaining exclusive, perpetual rights and a team, with expected rapid accretion and $6 million in annual revenue from existing contracts.